Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Nabs Advanced BioHealing Before It Can Test the Public Waters

This article was originally published in The Pink Sheet Daily

Executive Summary

Diversifying further, the specialty outfit will spend $750 million in cash for the regenerative medicine firm and its marketed wound-healing cell therapy product.

You may also be interested in...



Radius Raises $91 Million, Moves Toward Public Listing

Just two years ago Radius Health Inc. had a straightforward partnering strategy for its osteoporosis drug, BA058. Now that a key partner has opted not to exercise its option on the compound, Radius has instead raised a massive new round of funding that allows the company to keep full ownership of the compound. In addition, the crafting of a creative exit strategy alongside the financing paves a path to liquidity for its shareholders.

Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing

Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.

Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing

Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.

Related Content

Topics

UsernamePublicRestriction

Register

PS072249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel